Matthias Zeis

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Peter Dreger, Hartmut Döhner, Matthias Ritgen et al. · Blood · 2010 · 304 citations · Full text

Medicine, Immunology, Oncology +15

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

E. K., Uta Bertsch, Jan Dürig et al. · Leukemia · 2015 · 141 citations

Medicine, Oncology, Pharmacotherapy +14

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

Justin Hasenkamp, Gerald Wulf, Peter Dreger et al. · The Lancet Oncology · 2014 · 109 citations

Medicine, Immunology, Oncology +16

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Peter Dreger, Andrea Schnaiter, Thorsten Zenz et al. · Blood · 2013 · 105 citations · Full text

Medicine, Hematology, Oncology +13